top-evidence-and-studies-showing-the-covid-19-vaccines-pose-serious-blood-clotting-risks

Top Evidence and Studies Showing the COVID-19 ‘Vaccines’ Pose Serious Blood Clotting Risks


Here is a list of studies and other scientific evidence linking the COVID-19 “vaccines” to serious blood clotting risks, including cerebral venous sinus thrombosis and vaccine-induced thrombocytopenia.


KEY TERMS

  • Thrombosis – the formation or presence of a blood clot within a blood vessel.
  • Thrombocytopenia – a condition caused by a low blood platelet count.
  • Cerebral venous sinus thrombosis (CVST) – a condition caused when a blood clot forms in the brain’s venous sinuses.
  • D-dimer test – a blood test that measures D-dimer, a protein fragment that one’s body makes when a blood clot dissolves in their body.

Although the mainstream media often downplays the risk of developing harmful blood clots as a side effect of the COVID-19 “vaccines,” it’s there, and it’s significant. Collected here is just a portion of the evidence supporting that claim—including 14 studies from peer-reviewed journals—which, while incomplete, is substantive enough in itself to cause great alarm.

First off, Paul Offit, Professor of pediatrics at the Children’s Hospital of Philadelphia, noted in a YouTube video on July 14, 2021 that “serious blood clots… seem to occur in roughly one person per 500,000 that get the vaccine. The blood clots are serious because they can involve the spleen, they can involve areas of the intestine, and they can involve the brain.” Offit added that “The brain one is called cerebral venous sinus thrombosis… . So there are these common blood clots, then there are these very very very very rare blood clots that can be caused by the Johnson and Johnson vaccine.”

Offit added in the video (immediately below) that : “The blood clots that are caused by this J&J vaccine are associated with something called thrombocytopenia, which is a lowering of the platelet count” and that “in the people who have these blood clots they have two things that normally people who have blood clotting don’t have: They have a lowering of platelet count, and they also have antibodies in their bloodstream directed against platelet factor 4.

While Offit downplays the frequency of these “serious blood clots,” study after study has found an elevated risk of clotting after receiving one of the available COVID-19 “vaccines”—particularly the AstraZeneca “vaccine.” In fact, a study published in the journal Maxillofacial Plastic and Reconstructive Surgery on January 13, 2020 noted that “In April 2021, 86 potential cases of thrombosis and clots, out of 25 million vaccinated people, were reported. The blood clots have been tentatively linked to a syndrome causing unwanted immune response against platelet factor 4 after administration of adenoviral vector vaccines.” This figure, 86 out of 25,000,000, would mean one of these clotting events occurs every 290,698 “vaccinations” administered; meaning the serious adverse event is almost twice as common as Offit claimed in July of 2021.

Incredibly, a study published in The Journal of Autoimmunity in June of 2021 Cari et al. found that When considering AEs caused by thrombocytopenia, bleeding and blood clots, we observed 33 and 151 SAEs/1 million doses in BNT and ChA recipients, respectively. The authors also found that “When considering patients with AEs related to cerebral/splanchnic venous thrombosis, and/or thrombocytopenia, we documented 4 and 30 SAEs and 0.4 and 4.8 deaths/1 million doses for BNT and ChA recipients, respectively.” Meaning the authors found an average of 151 severe adverse events per one million doses of the AstraZeneca “vaccine” and 33 adverse events/per million for the Pfizer one.

Indeed, these clotting events are extremely serious, and have been, on many instances in the literature, fatal. In a study published in The New England Journal of Medicine on April 9, 2021, Schultz et al. reported that “Within 10 days after receiving a first immunization with ChAdOx1 nCoV-19 [the AstraZeneca “vaccine”], five health care workers 32 to 54 years of age presented with thrombosis in unusual sites and severe thrombocytopenia. Four of the patients had major cerebral hemorrhage.” the authors went on to note that one patient, a 37-year-old woman, developed severe thrombocytopenia; she went on to experience a massive cerebellar hemorrhage and died in the hospital. Patient 2, likewise, died after her “vaccination” due to blood clotting; experiencing a venous thrombosis with occlusion of the transverse and sigmoid sinuses and hemorrhagic infarction in the left hemisphere of her 42-year-old body.

Not only is there a clear adverse event signal in relation to clotting in the literature, as well as numerous (often fatal) case reports, there are also obvious, fully acknowledged mechanisms of action for clotting. A study in The Journal of Hematology and Oncology published September 4, 2020 noted that “SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients.” The study also found that the SARS-CoV-2 spike protein “enhanced thrombosis formation.”

A study published in The Journal of Current Science and Technology on January 25, 2022 noted that a literature review has “implied the mechanisms inducing this condition arise from an induction of platelet-activating antibodies against PF4.” A finding that supports Offit’s claim that people who experience vaccine-induced thrombosis have antibodies in their bloodstream directed against platelet factor 4.

In a letter to the editor in The British Medical Journal published March 11, 2021 (excerpted immediately below) medical professor viroj wiwanitkit, in Pune, India, notes something else about post-vaccination clotting: the incidence of blood clots post vaccination appears to increase if somebody has had a previous SARS-CoV-2 infection; meaning forcing a “vaccination” upon somebody with prior immunity is not only useless, but also exceptionally dangerous.

“The blood clots formation after COVID-19 vaccination is an interesting issue. Regarding the thrombosis triad, the effect of vaccine might be on blood viscosity. The post vaccination stimulation of immune response might relate to the problem. In a recent report, a person with evidence of previous infection has a significant more immune response. This might be a possible cause of hyperviscosity, an important component of thrombogenesis. Anyone with underlying vascular disease should be carefully evaluated before vaccination. It is also questionable whether there should be a prevaccination screening for SARS VoV2 antibody.”


14 STUDIES DEMONSTRATING DANGERS OF CLOTTING DUE TO COVID-19 “VACCINATION”

1. The British Medical Journal (Published August 27, 2021)

TITLE: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

METHODS: “Self-controlled case series study using national data on covid-19 vaccination and hospital admissions… . Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom’s health service (NHS).”

CONCLUSION: “The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events.

“The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test.

“Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.”

LINK TO STUDY


2. Health (Published February 18, 2022)

TITLE: A Case of Adverse Reaction to Booster Dose of COVID-19 Vaccination: Could D-Dimer Elevation Suggest Increased Clotting Risk?

ABSTRACT: “We report the clinical case of a 40-year-old Italian woman, who soon after her booster vaccination with mRNA-1273 after the two previous vaccinations with BNT162b2, developed severe headache, high fever, and Musculo-skeletal pain. She went to the emergency department, where computerized tomography (CT) scans of chest and brain were performed, resulting in both negative for pathologic findings. On the contrary, white blood count was strongly lowered and D-dimer severely elevated. She improved after treatment with enoxaparin and the blood analyses returned in the normal range after ten days. This case supports the hypothesis that COVID-19 vaccines could increase blood clotting in some predisposed subjects. Therefore, we believe that robust and well-designed clinical trials, considering the evaluation of D-dimer levels, should be performed to eliminate any doubts on this issue.

CONCLUSION: “In conclusion, as discussed above, the case of this Italian woman supports the idea that some clotting after COVID-19 vaccination can happen. Therefore, this important topic should be clarified as soon as possible to remove all doubt on the issue. We believe that robust and well-designed studies, always considering a D-dimer test, are needed to completely exclude that COVID-19 vaccines may promote thrombosis, particularly in some predisposed subjects, these are lacking at present.”

LINK TO STUDY


3. Journal of Current Science and Technology (Published on January 25, 2022)

TITLE: Unusual blood clots with low blood platelets from Covid-19 viral vector vaccines

ABSTRACT: “In providing human immunity from the SARS-CoV-2 virus, AstraZeneca’s ChAdOx1 nCov-19 vaccines have been administered in multiple nations around the world. Throughout this literature review, the background behind derivation of this vaccine from chimpanzees to avoid pre-existing human immunity to this adenoviral vector’s mechanism of interactions will be discussed prior to clinical issues this vaccine brings. Arranged in sections, this discussion concerns the adenovector vaccine’s ability to induce both innate and adaptive immunity, featuring the mucosal route of administration’s ability to stimulate tissue-resident memory T cells (TRM), a crucial part of the adaptive immune system.
Despite its solid ability to stimulate immunity with high efficiency and efficacy, a surge in female fatalities following administrations of the ChAdOx1 nCov-19 adenovector vaccines have also occurred. Published articles regarding both hypothesised mechanisms as well as recorded incidences of this rare vaccine-induced blood clots, also known as the Thrombosis and Thrombocytopenia Syndrome (TTS), have been discussed. Despite still lacking a causal relationship between AZ administrations in heparin-free patients and TTS incidences, all of these articles have implied the mechanisms inducing this condition arise from an induction of platelet-activating antibodies against PF4. The most plausible arisal of these antibodies is from free DNA molecules within the ChAdOx nCov-19 vaccine. Additionally, TTS draws similarities to autoimmune heparin-induced thrombocytopenia cases, where a platelet count decline also occurs.”

CONCLUSION: “The adenoviral vector definitely fulfills the criteria of stimulating appropriate immune
responses. However, its mechanism of action is also responsible for health issues involved with the vaccine. Although infrequent, reports of blood clots linked to decreased blood platelet counts have been made subsequently to administration of the COVID-19 vaccines of AstraZeneca (AZ) or Johnson & Johnson (J&J) (Aladdin, Algahtani, & Shirah, 2021; Marcucci & Marietta, 2021). This condition is identified as basis with Thrombocytopenia Syndrome, or TTS for short. According to earlier media reports, indications that ageing females suffered increased risks of developing this condition were not proven true yet, and that there are currently no indications of any risk elements which heightens a person’s susceptibility to TTS (Tsilingiris, Vallianou, Karampela, & Dalamaga, 2021). The TTS
condition is defined by these three symptoms (De Cristofaro & Sanguinetti, 2021; Lavin et al., 2021).
Firstly, it is venous or arterial thrombosis (De Cristofaro & Sanguinetti, 2021; Lavin et al., 2021). It is more probable to conclude for TTS if it occurs at unexpected sites such as with cerebral sinus venous thrombosis (CSVT) (De Cristofaro & Sanguinetti, 2021). These are unusual manifestations of the more common venous thromboembolism (Abou-Ismail, Moser, Smock, & Lim, 2021). Secondly, symptoms of TTS include mild to severe thrombocytopenia (Marcucci & Marietta, 2021).”

LINK TO STUDY

[NOTE: The WHO released the above study as a part of its body of “COVID-19 global literature on coronavirus disease.”]


4. Maxillofacial Plastic and Reconstructive Surgery (Published January 13, 2022)

TITLE: Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?

METHODS: A multicenter electronic questionnaire via an online platform was conducted over a 1-week period among vaccinated dental staff and dental students inquiring whether they experienced vaccine-related side-effects after vaccine administration.

CONCLUSION:

“In April 2021, 86 potential cases of thrombosis and clots, out of 25 million vaccinated people, were reported. The blood clots have been tentatively linked to a syndrome causing unwanted immune response against platelet factor 4 after administration of adenoviral vector vaccines. There is a possibility that phase 3 reports of clotting are susceptible to biases and higher numbers of reports are expected in the near future. Despite the fact that the findings of a questionnaire-based survey is not powered to address serious side effects after vaccination, it necessitates the need for further clinical assessments with large sample sizes.”

“93.2% of vaccinated population experienced at least one side effect. 7 cases of thrombosis and blood clotting (1.64%) and 4 mild allergic reactions (0.93%) were reported after Gam-COVID-Vac administration.”

“In our study, rare cases of serious events after vaccination were reported; 20 cases of thrombosis and blood clotting (10 ChAdOx1 nCoV-19, 7 Gam-COVID-Vac, and 3 BBIBP-CorV groups), one moderate, and one serious (both were reported in ChAdOx1 nCoV-19 group). Also 10 cases of mild allergic reactions (6 in ChAdOx1 nCoV-19 and 4 in Gam-COVID-Vac group) and 1 moderate level (ChAdOx1 nCoV-19) were reported.”

“The commonly reported adverse events were in line with similar studies. We have concerns with the frequency of serious adverse effects. This work necessitates the need for further clinical assessments with larger sample sizes.”

LINK TO STUDY


5. Critical Care Medicine (Published July 13, 2021)

TITLE: Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia

METHODS: Online search of published medical literature through PubMed, Scopus, Web of Science, and Google Scholar using the terms “COVID-19,” “vaccine,” “thrombosis” was performed. Articles were chosen for inclusion based on their relevance to coronavirus disease 2019, vaccine, and thrombosis.

Toshiaki Iba et al. / Critical Care Medicine

CONCLUSION: “Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) as treatment is initiated (nonheparin anticoagulation, IV immunoglobulin).”

“A striking unresolved question is why CVST [cerebral venous sinus thrombosis] is so common in VITT [vaccine-induced immune thrombotic thrombocytopenia]. CVST is rare, accounting for less than 1% of strokes. Non-VITT CVST is reported in the relatively younger patients, with 70% younger than 50 years old and more common in females. Further studies of VITT pathogenesis may help in a better understanding of CVST occurrence.”

LINK TO STUDY


6. International Journal of Infectious Diseases (Posted April 2022)

TITLE: Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA–1273 vaccine: A case report

METHODS: “We report a case of a Japanese man with severe rhabdomyolysis and multiple thrombosis of arterioles after the first dose of mRNA-1273 vaccine. He developed rapidly progressive rhabdomyolysis and infarctions of multiple organs. Antiplatelet factor 4 antibody test was negative. Despite the intensive supportive care, including aggressive fluid administration, hemodialysis, administration of anticoagulants, high-dose steroid, and eculizumab, the patient ultimately died of multiple organ failure. Autopsy revealed multiple thrombosis in the arterioles and organ necrosis. Low serum complements and C3 deposition in the renal glomeruli detected by immunofluorescence suggested a possible immune-mediated mechanism. To our knowledge, this is the first case report of rhabdomyolysis and multiple thrombosis of the arterioles as an adverse event following COVID-19 vaccination.”

Yuyu Kamura et al. / International Journal of Infectious Diseases

DISCUSSION: “The patient’s clinical course was complicated by severe rhabdomyolysis, severe kidney failure, and massive bleeding in the gastrointestinal tract and iliopsoas due to multiple thrombosis of the small arteries. We initially treated the rhabdomyolysis with intravenous fluid administration but his serum CK level continued to rise with a peak level of 74,804 U/L 4 days after admission and his renal function deteriorated rapidly, requiring hemodialysis. Follow-up CT revealed the multiple contrast defects in the liver and kidneys, suggesting hepatic and renal infarctions; however, thrombosis of the large vessels was not identified. We started the patient on argatroban therapy, followed by anticoagulation with heparin, high-dose methylprednisolone, and intravenous immunoglobulin. However, massive bleedings in the gastrointestinal tract and right iliopsoas muscle developed, which prevented further use of anticoagulants. Because serum complement levels of C3c, C4, and CH50 were decreased to 29, 19 mg/dL, and 14.3 U/mL, respectively, we started the patient on eculizumab for the potential complement activation but no beneficial effect was obtained. The patient ultimately died 18 days after admission to our hospital.”

LINK TO STUDY


7. Neurology (Published February 15, 2022)

TITLE: Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination

METHODS: “We estimated the absolute risk of CVST with and without thrombocytopenia within 28 days of a first dose of 4 SARS-CoV-2 vaccinations using data from the European Medicines Agency’s EudraVigilance database (until June 13, 2021). As a denominator, we used data on vaccine delivery from 31 European countries. For 22.8 million adults from 25 countries, we estimated the absolute risk of CVST after the first dose of ChAdOx1 nCov-19 per age category.”

CONCLUSION: “The absolute risk of CVST within 28 days of first-dose vaccination was 7.5 (95% confidence interval [CI] 6.9–8.3), 0.7 (95% CI 0.2–2.4), 0.6 (95% CI 0.5–0.7), and 0.6 (95% CI 0.3–1.1) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. The absolute risk of CVST with thrombocytopenia within 28 days of first dose vaccination was 4.4 (95% CI 3.9–4.9), 0.7 (95% CI 0.2–2.4), 0.0 (95% CI 0.0–0.1), and 0.0 (95% CI 0.0–0.2) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. In recipients of ChAdOx1 nCov-19, the absolute risk of CVST, both with and without thrombocytopenia, was the highest in the 18- to 24-year-old group (7.3 per million, 95% CI 2.8–18.8 and 3.7 per million, 95% CI 1.0–13.3, respectively). The risk of CVST with thrombocytopenia in ChAdOx1 nCov-19 recipients was the lowest in the age group ≥70 years (0.2, 95% CI 0.0–1.3). Age <60 years compared to ≥60 years was a predictor for CVST with thrombocytopenia (incidence rate ratio 5.79, 95% CI 2.98–11.24, p < 0.001).”

The risk of CVST with thrombocytopenia within 28 days of first-dose vaccination with ChAdOx1 nCov-19 was higher in younger age groups. The risk of CVST with thrombocytopenia was slightly increased in patients receiving Ad26.COV2.S compared with the estimated background risk. The risk of CVST with thrombocytopenia was not increased in recipients of SARS-CoV-2 mRNA vaccines.”

LINK TO STUDY


8. Journal of Autoimmunity (Published June 2021)

TITLE: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data

METHODS: The involvement of viruses and SARS-CoV-2 in autoimmune diseases is well known. The recent demonstration that ChAdOx1 nCoV-19 Covid-19 (AstraZeneca) vaccine (ChA) favors the production of anti-platelet factor 4 (anti-PF4) antibodies, blood clots, and thrombocytopenia raises the question of whether other anti-CoViD-19 vaccines favor the same patterns of events. We assessed the frequency of severe adverse events (SAEs) documented in the EudraVigilance European database up to April 16, 2021 related to thrombocytopenia, bleeding, and blood clots in recipients of ChA compared to that of recipients of the BNT162b2 Covid-19 (Pfizer/BioNTech) vaccine (BNT). ChA administration was associated with a much higher frequency of SAEs in each AE Reaction Group as compared with that elicited by BNT. When considering AEs caused by thrombocytopenia, bleeding and blood clots, we observed 33 and 151 SAEs/1 million doses in BNT and ChA recipients, respectively. When considering patients with AEs related to cerebral/splanchnic venous thrombosis, and/or thrombocytopenia, we documented 4 and 30 SAEs and 0.4 and 4.8 deaths/1 million doses for BNT and ChA recipients, respectively. The highest risk following ChA vaccination is in young people and, likely, women of reproductive age, as suggested by hypothesized scenarios. In conclusion, the immune reaction promoted by ChA vaccine may lead to not only thrombocytopenia and cerebral/splanchnic venous thrombosis but also other thrombotic and thromboembolic SAEs. These events are not favored by BNT vaccine. Our study may help in the evaluation of the benefit/risk profile of the ChA vaccine considering the epidemic curve present in a country.

EXCERPTS FROM CONCLUSION: “Out of OMDs administered, 35.5 and 151.4 SAEs related to thrombocytopenia and blood clots were reported for recipients of BNT or ChA, respectively. If considering that the event frequency observed in BNT recipients was equal to the frequency of the same event in the untreated population, then 1 SAE out of ~9000 ChA recipients was observed (HR >4). Moreover, following OMD administration of BNT or ChA, respectively, 4.4 and 13.1 deaths possibly related to thrombocytopenia/bleeding and blood clots were reported, respectively, representing an excess of ~9 deaths/OMDs (HR =3) in ChA recipients. Our data disagree with the data reported by the EMA (1 SAE per ~100,000 doses concerning thrombocytopenia and blood clots).”

Following OMD administration of BNT or ChA, respectively, 0.8 and 10 SAEs caused by CVT, 0.2 and 2.9 SAEs by SVT, and 3.1 and 23.3 SAEs by thrombocytopenia, respectively, were reported. Following OMD administration of BNT or ChA, respectively, the risk of death for CVT was 0.1 and 2.5/OMDs, for SVT was 0.0 and 0.4/OMDs and for thrombocytopenia was 0.3 and 3.9/OMDs.”

LINK TO STUDY


9. Journal of Hematology and Oncology (Published September 4, 2020)

TITLE: SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

METHODS: “For this study, we recruited COVID-19 patients admitted to the First Affiliated Hospital of Zhengzhou University, Henan Province, China and three centers of the Affiliated Hospital of Anhui Medical University, Anhui Province, China between January 10th and March 18th, 2020. The detailed study design, including the inclusion and exclusion criteria as well as laboratory data collection, is described in Additional file 1: Expanded Materials and Methods. This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2020-KY-121) and the Ethics Committee of Anhui Medical University (2020-AH-114) and complied with the Declaration of Helsinki and good clinical practice guidelines. All participants provided written informed consent.”

CONCLUSION: “We demonstrated that COVID-19 patients present with increased mean platelet volume (MPV) and platelet hyperactivity, which correlated with a decrease in overall platelet count. Detectable SARS-CoV-2 RNA in the blood stream was associated with platelet hyperactivity in critically ill patients. Platelets expressed ACE2, a host cell receptor for SARS-CoV-2, and TMPRSS2, a serine protease for Spike protein priming. SARS-CoV-2 and its Spike protein directly enhanced platelet activation such as platelet aggregation, PAC-1 binding, CD62P expression, α granule secretion, dense granule release, platelet spreading, and clot retraction in vitro, and thereby Spike protein enhanced thrombosis formation in wild-type mice transfused with hACE2 transgenic platelets, but this was not observed in animals transfused with wild-type platelets in vivo. Further, we provided evidence suggesting that the MAPK pathway, downstream of ACE2, mediates the potentiating role of SARS-CoV-2 on platelet activation, and that platelet ACE2 expression decreases following SARS-COV-2 stimulation. SARS-CoV-2 and its Spike protein directly stimulated platelets to facilitate the release of coagulation factors, the secretion of inflammatory factors, and the formation of leukocyte–platelet aggregates. Recombinant human ACE2 protein and anti-Spike monoclonal antibody could inhibit SARS-CoV-2 Spike protein-induced platelet activation.”

“Our findings uncovered a novel function of SARS-CoV-2 on platelet activation via binding of Spike to ACE2. SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients.”

LINK TO STUDY


10. American Journal of Hematology (Published on March 9, 2021)

TITLE: Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination

METHODS: “Cases of apparent secondary immune thrombocytopenia (ITP) after SARS‐CoV‐2 vaccination with both the Pfizer and Moderna versions have been reported and reached public attention. Public alarm was heightened following the death of the first identified patient from an intracranial hemorrhage, which was reported on the Internet, then in USA Today and then in The New York Times. Described below, we have collected a series of cases of very low platelet counts occurring within 2 weeks of vaccination in order to enhance our understanding of the possible relationship, if any, between SARS‐CoV‐2 vaccination and development of ITP with implications for surveillance and management.”

EXCERPTS: “Twenty case reports of patients with thrombocytopenia following vaccination, 17 without pre‐existing thrombocytopenia and 14 with reported bleeding symptoms prior to hospitalization were identified upon review of data available from the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), agencies of the U.S. Department of Health and Human Services (HHS) Vaccine Adverse Events Reporting System (VAERS), published reports, and via direct communication with patients and treating providers. These cases were investigated as suspicious for new onset, post‐vaccination secondary ITP; we could not exclude exacerbation of clinically undetected ITP. Search terms relating to ‘decreased platelet count,’ ‘immune thrombocytopenia,’ ‘hemorrhage,’ ‘petechiae,’ and ‘contusion’ were utilized to identify cases reported in VAERS.”

“The reports describing 19 of 20 patients included age (range 22–73 years old; median 41 years) and gender (11 females and 8 males). Nine received the Pfizer vaccine and 11 received the Moderna vaccine. All 20 patients were hospitalized and most patients presented with petechiae, bruising or mucosal bleeding (gingival, vaginal, epistaxis) with onset of symptoms between 1–23 days (median 5 days) post vaccination. Platelet counts at presentation were available for all 20 cases with the majority being at or below 10 × 109/L (range 1–36 × 109/L; median 2 × 109/L).”

“In the absence of pre‐vaccination platelet counts and given the variable time post vaccination to discovery of thrombocytopenia, it is impossible to precisely estimate the incidence of secondary ITP post SARS‐CoV‐2 vaccination at this time. However, it is notable that all but one of the cases identified thus far occurred after the initial dose of SARS‐CoV‐2 vaccine. One would assume that if the vaccination was unrelated to development of ITP, case occurrences would divide more evenly between the two doses. It is also likely that the actual incidence of thrombocytopenia, including mild asymptomatic cases, may be higher and go unreported.”

“In summary, we cannot exclude the possibility that the Pfizer and Moderna vaccines have the potential to trigger de novo ITP (including clinically undiagnosed cases), albeit very rarely. Distinguishing vaccine‐induced ITP from coincidental ITP presenting soon after vaccination is impossible at this time. Additional surveillance is needed to determine the true incidence of thrombocytopenia post vaccination. If the incidence of thrombocytopenia post vaccination is higher than that based on available case reports, we anticipate that many more cases will be reported in the coming weeks as a higher proportion of the population is vaccinated. It may be worthwhile to see whether exacerbations of other conditions considered to have an autoimmune pathophysiology occur as well to gain a better understanding of host response to vaccination.”

LINK TO STUDY


11. The Journal of Emergency Medicine (Published on March 9, 2021)

TITLE: Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine

METHODS: “Currently, the SARS-CoV-19 pandemic represents the leading global health emergency, and vaccines are the primary health strategy to eradicate this global challenge. In Europe, three vaccines have been approved by the European Medicines Agency (EMA), two based on mRNA technology, and one with an adenovirus vector [1]. Published data show high protective efficacy rates in the face of mostly mild-to-moderate and short-lasting adverse effects, mainly after the second dose. Venous thromboembolic (VTE) complications have been consistently reported to be increased in SARS-CoV-2 infection, most probably as the results of a thrombophilic state secondary to inflammation and immune-thrombosis. On the other hand, no reports are available regarding a possible association between VTE and SARS-Cov-2 post-vaccine acute-phase reaction. Here we describe a case of distal deep vein thrombosis occurring immediately days after the second dose of mRNA vaccine.”

CONCLUSION: “To our knowledge, this is the first reported case of DVT presenting as an adverse event post-SARS-CoV-2 vaccination. Arguably, the intense immunological response evoked by the second dose of vaccine could be a trigger for the thrombotic event described, a mechanism recognized in many clinical conditions. No DVT cases have been reported on 21,720 persons receiving BNT162b2, suggesting that the DVT incidence may be lower than one case every 5889 (this figure representing the 95% upper boundary of confidence interval). No apparent correlation can be made with the presence of a mild thrombophilia mutation in this patient. In our district, the vaccination program started on January 2021 and involved only health workers, of whom 3010 received two doses on January 25th. This case notwithstanding, we may consider that DVT post-vaccination incidence may still be very low and within the expected incidence figure. A longer follow-up and a greater diffusion of SARS-CoV-2 vaccines in the population are needed to clarify the magnitude of this potential side effect—that, although extremely low, may not be negligible on a population-wide basis.”

LINK TO STUDY


12. Medical Archive / Not yet peer-reviewed (Published March 8, 2021)

TITLE: SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by unprecedented clinical pathologies. One of the most important pathologies, is hypercoagulation and microclots in the lungs of patients. Here we study the effect of isolated SARS-CoV-2 spike protein S1 subunit as potential inflammagen sui generis. Using scanning electron and fluorescence microscopy as well as mass spectrometry, we investigate the potential of this inflammagen to interact with platelets and fibrin(ogen) directly to cause blood hypercoagulation. Using platelet poor plasma (PPP), we show that spike protein may interfere with blood flow. Mass spectrometry also showed that when spike protein S1 is added to healthy PPP, it results in structural changes to β and γ fibrin(ogen), complement 3, and prothrombin. These proteins were substantially resistant to trypsinization, in the presence of spike protein S1. Here we suggest that, in part, the presence of spike protein in circulation may contribute to the hypercoagulation in COVID-19 positive patients and may cause substantial impairment of fibrinolysis. Such lytic impairment may result in the persistent large microclots we have noted here and previously in plasma samples of COVID-19 patients. This observation may have important clinical relevance in the treatment of hypercoagulability in COVID-19 patients.

Lize M. Grobbelaar et al.

CONCLUSION: “An interesting observation was that clots from healthy PPP could easily be dislodged by
flushing the flow channel with water at a rate of 1mL.min-1 (0.42m.s-1). Similarly, clots from
healthy PPP with added spike protein could be dislodged in a similar fashion. COVID-19
clots, on the contrary, could not be displaced or dislodged and remained intact, even with
the force of high-speed water flow in a small flow channel. This observation was consistent
for all the COVID-19 samples.”

LINK TO STUDY


13. The New England Journal of Medicine (Published on April 9, 2021)

TITLE: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

METHODS: “We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age. All the patients had high levels of antibodies to platelet factor 4–polyanion complexes; however, they had had no previous exposure to heparin. Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia.”

EXCERPTS FROM CASE STUDIES: “The European Medicines Agency has approved five vaccines against coronavirus disease 2019 (Covid-19), and more than 600 million doses have been administered globally. In Norway, older adults living in institutional settings and health care professionals who are in close contact with patients with Covid-19 have been prioritized to receive the BNT162b2 mRNA Covid-19 vaccine (Pfizer–BioNTech). In addition, the ChAdOx1 nCoV-19 vaccine (AstraZeneca) has been administered to health care professionals younger than 65 years of age who do not have close contact with patients with Covid-19. As of March 20, 2021, when administration of the vaccine was paused, a total of 132,686 persons in Norway had received the first dose of the ChAdOx1 nCoV-19 vaccine and none had received the second dose.

Within 10 days after receiving a first immunization with ChAdOx1 nCoV-19, five health care workers 32 to 54 years of age presented with thrombosis in unusual sites and severe thrombocytopenia. Four of the patients had major cerebral hemorrhage. Here we describe this vaccine-induced syndrome of severe thrombosis and thrombocytopenia found among these five patients admitted to Oslo University Hospital.

“Patient 1 was a 37-year-old woman with headaches that developed 1 week after vaccination with ChAdOx1 nCoV-19. At presentation to the emergency department the next day, she had fever and persistent headaches. She was found to have severe thrombocytopenia. Computed tomography (CT) of the head showed thrombosis in the left transverse and sigmoid sinuses. Because of the low platelet count, a reduced dose of dalteparin (2500 IU daily) was given. The next day, her clinical condition deteriorated, and a new CT scan showed a massive cerebellar hemorrhage and edema in the posterior fossa. She was treated with platelet transfusions and decompressive craniectomy. During surgery, massive and uncontrollable edema developed. The patient died on day 2 after surgery.”

“Patient 2 was a 42-year-old woman who had headaches 1 week after vaccination with ChAdOx1 nCoV-19. Her condition worsened rapidly, and she presented with reduced consciousness at presentation to the emergency department 3 days later. Her platelet count was 14,000 per cubic millimeter. ADAMTS13 activity was found to be normal. CT venography revealed venous thrombosis with occlusion of the transverse and sigmoid sinuses and hemorrhagic infarction in the left hemisphere. Hemicraniectomy was performed, and treatment with dalteparin at a dose of 2500 IU daily was initiated. She received multiple platelet transfusions over the following days. On day 8, methylprednisolone (1 mg per kilogram of body weight per day) and intravenous immune globulin (1 g per kilogram per day) were administered. The platelet count increased thereafter. However, the patient died after 2 weeks in the intensive care unit (ICU) from increased intracranial pressure and severe cerebral hemorrhagic infarction on day 15.”

LINK TO STUDY


14. Vaccines (Published May 18, 2022)

TITLE: Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database

METHODS: “In our observational case–control study, we extracted all ADR cases of CVT related to mRNA-based COVID-19 vaccines and the ChAdOx1 nCoV-19 vaccine reported in VigiBase using the following preferred terms for CVT in the Medical Dictionary for Drug Regulatory Activities from 20 October 2021: “transverse sinus thrombosis”, “superior sagittal sinus thrombosis”, “cerebral venous sinus thrombosis”, and “cerebral venous thrombosis”. Information was obtained about age, sex, type of vaccine, time to CVT onset, reporting continents, seriousness, and final outcomes. Seriousness was defined as resulting in significant disability/incapacity, requiring hospitalization, life-threatening, and death. To confirm the differences in the occurrence of CVT by vaccine, the daily numbers of CVT cases were compared over four weeks among the three COVID-19 vaccines.”

CONCLUSION: “The key findings of our study of CVT cases from VigiBase reported by 130 countries are that the potential safety signal for the development of CVT was noted in mRNA-based COVID-19 vaccines as well as the ChAdOx1 nCoV-19 vaccine compared with the entire dataset.”

“Interestingly, our results showed that there was a difference in the onset of CVT after exposure to the mRNA-based COVID-19 vaccines and ChAdOx1 nCoV-19 vaccine. The median values of 13 and 11 days for the time to onset of CVT for the mRNA-based COVID-19 vaccines and the ChAdOx1 nCoV-19 vaccine, respectively, were similar. However, the mRNA-based COVID-19 vaccines had the highest number of CVT cases in the first week after vaccination, after which the incidence decreased gradually. In contrast, the ChAdOx1 nCoV-19 vaccine showed the highest incidence of CVT in the second week after vaccination and a sharp decrease thereafter. These timelines suggest that the thrombosis mechanisms of these vaccines differ. The mRNA-based COVID-19 vaccines, which target the spike glycoprotein of SARS-CoV-2, directly induce intracellular production of the spike protein. This spike protein plays a key role in the initiation of the immune response, which may last for up to a few weeks. CVT occurred from 1 to 9 days after vaccination, and the neutralizing antibody titer after vaccination was maintained for 35 to 119 days. This evidence supports a wide temporal distribution of CVT occurrence related to mRNA-based COVID-19 vaccination in our study. In contrast, the formation of PF4 antibodies and PF4–polyanion complexes in vaccine-induced immune thrombotic thrombocytopenia, the most well-known thrombotic complication after ChAdOx1 nCoV-19 vaccination, takes time. A type-II heparin-induced thrombocytopenia that develops via a similar mechanism occurs 5 to 14 days after exposure due to the time required for the formation of antibodies. In another study of the ChAdOx1 nCoV-19 vaccine, CVT was reported 5 to 30 days (median 14 days) after vaccination. Regardless, it is possible that other mechanisms of thrombosis have not yet been elucidated.

“In this study, the time until CVT occurrence after vaccination was significantly different between the BNT162b2 and ChAdOx1 nCOV-19 vaccines but not between the mRNA-1273 and ChAdOx1 nCOV-19 vaccines. Various factors, such as vaccine components or immune responses, might cause this difference between mRNA vaccines. However, our study could not provide acceptable evidence related to these differences. Recently, several studies that compared the BNT162b2 and mRNA-1273 vaccines reported the possibility of differences in clinical responses or outcomes in addition to SARS-CoV-2 antibody responses. The rates of breakthrough infections and 60-day hospitalizations were significantly lower in those vaccinated with mRNA-1273 compared with BNT162b2; this result suggests that these vaccines may act via different mechanisms. Further studies on the specific mechanism of CVT occurrence after mRNA vaccination and prospective studies on clinical outcomes are needed.

“In our study, the number of deaths in CVT patients was lower after mRNA vaccination than after vaccination with ChAdOx1 nCoV-19. A previous study showed that significant risk factors for mortality due to thrombosis with thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination were intracerebral hemorrhage and CVT. However, there have been few studies on CVT occurrence after mRNA vaccination and CVT-related mortality. Furthermore, it is difficult to present accurate evidence because VigiBase does not provide information on various parameters related to mortality, such as laboratory data, brain-imaging findings, or the occurrence of systemic thromboembolism.”

LINK TO STUDY


VAERS REPORTS

Along with literature reviews and case studies providing extensive evidence of serious clotting risks, VAERS (the Vaccine Adverse Event Reporting System) also demonstrates clotting as a common, adverse effect of the COVID-19 “vaccines.” Searching the (COVID-19 vaccine-only) database for the term “blood clot,” for example, turns up 13,683 results. Thrombosis: 18,870 results. Thrombocytopenia: 6,850 results.

A very small sample of some of the VAERS reports that include the term “blood clot” are immediately below.

LINK TO VAERS SEARCH PAGE


DISCUSSION OF VACCINE-RELATED CLOTTING WITH DR. RYAN COLE

In the video immediately below, Steve Kirsch, the inventor of the optical mouse, founder of several multi-billion-dollar companies, and founder of the COVID-19 Early Treatment Fund (CETF) speaks with now-iconic Dr. Ryan Cole, a pathologist from Idaho, about the clotting effects of the “vaccines.”

LINK TO VIDEO

Embalmers have reported that they’re seeing these unusual clots that they’ve never seen before, and it only started after the vaccines started to roll out and it seems only to be in vaccinated patients,” Kirsch says in the video. “So I had one embalmer who had multiple cases and they knew which had the telltale clots and which didn’t have the telltale and they went back and looked at the vaccination status and it matched up 100% to what they observed.”

“Most of the docs who are thinking and engaging [in the issues of clotting after “vaccination”] are saying it has got to be microclots,” Cole says in the video. “And to that point… I see it in the skin [with] biopsies and microclots. A colleague down in Texas who’s a GI pathologist… after the shots rolled out, he [said] he’s seen tons of microclots in his biopsies.” Cole goes on to note that these clots are “kind of anchored to the wall of the vessel, and then you kind of have this big, polyp-y plug and for a while it’s kind of this flappy valve and blood tries to work around it… but as it grows, it ends up blocking off [blood flow].”

Image: Dr. Ryan Cole

Cole discusses blood clots up to three feet in length that morticians have pulled out from bodies. “The dose of spike protein makes the poison. There was a Stanford study that came out… that showed how long the mRNA is still persisting in the lymph nodes and still generating spike. [U]p to 60 days this synthetic mRNA is making spike… .” Cole cites a study in which spike protein led to “incredibly abnormal” blood clots in in vitro blood samples.

Cole notes that the body isn’t breaking down these clots “normally” either. This, he says, is because the spike protein bypasses all the normal steps that would usually be necessary to make a clot and is “instantaneously” causing a clot. And/or causing clots slowly over time. (In the image above is a comparison from Cole’s slides showing a normal blood clot—right—and an abnormal one caused by spike protein.)

Richard Hirschman via Dr. Jane Ruby

Immediately below is an excerpt of an interview with board-certified embalmer Richard Hirschman. According to Hirschman, who’s been an embalmer for more than 20 years, he “has been finding these strange clots [starting] around middle of last year [2021].

Hirschman goes on to present blood clots he’s found with a white coloration and fibrous texture. He notes these blood clots are “pretty strong” and “not weak at all” like normal clots are.

“I could literally rinse these clots, rub the blood off of them, and this white stuff holds strong. It does not dissolve—you can break it, but it’s stretchy. Hirschman—who’s now inadvertently inspiring Reddit threads—goes on to note that “I contacted colleagues of mine and they’re all seeing the same thing.”


ANECDOTAL EXAMPLES OF BLOOD CLOTS AFTER COVID-19 “VACCINATION”

Along with the literature reviews, case studies, VAERS reports, and testimony from at least one prominent pathologist and career embalmer, there are also countless anecdotal stories of clotting after COVID-19 “vaccination” online. Immediately below are just a handful of the horrifying examples of real people developing serious blood clots due to the COVID-19 “vaccines.”


1. A man in British Columbia, Shaun Mulldoon, develops a “massive blood clot” 17 days after receiving the AstraZeneca “vaccine.” Doctors had to remove over six feet of his small intestine. This was the second case of such a clotting incident in BC at the time.

LINK TO VIDEO


2. Colorado Springs resident Kendra Lippy says after she got the Johnson and Johnson vaccine she developed “extreme blood clots” and “slipped into a coma for almost a month.” The entire middle of her small intestine had to be removed due to the clots.

LINK TO VIDEO

3. Australian woman on TikTok describes how she received the vaccine after being told, in essence, “no jab, no job.” The self-proclaimed “super active” 19-year-old woman describes how she began to experience adverse side effects the night of her second Pfizer dose, including soreness, blurred vision, and a “really bad headache.” She soon learned that her whole body—including legs, chest, and lungs—was filling up with blood clots and she had to be rushed to the hospital.

LINK TO VIDEO

4. A woman describes how her mother’s podiatrist wouldn’t perform surgery on her mother’s foot unless she received her second dose of the “vaccine.” After her second shot, the woman describes how her mother started having chest pains, and eventually developed a blood clot in her leg.


5. A woman describes how her healthy 41-year-old brother, Orlando Ferreira, died after having a heart attack “a few days” after vaccination. Ferreira’s sister goes on to note that the man’s death certificate notes “multi-organ failure” as the cause. Ferreira’s sister adds that “his own body was attacking itself because of the ‘so-called’ vaccine.”

LINK TO VIDEO

6. A woman describes how she was hospitalized for shortness of breath, fever “on and off,” chills, congestion, etc. approximately seven months after vaccination. The woman notes that while in the hospital doctors believed she had a blood clot in her lung. Indeed, the woman notes doctors believe it was (at the time of this video) a “suspicious nodule.”

LINK TO VIDEO

7. Twenty eight-year-old woman, Elizabeth Rogers, develops a “dangerous blood clot in her brain” 9-10 days after receiving the Johnson and Johnson “vaccination.” Rogers notes in the video, “I feel like it was a death sentence… . Because it was just horrible nausea, horrible headaches, body aches, a slight fever at one time.” Rogers notes that doctors identified a blood clot “on the right side [of her brain] in one of the central veins…on the right side, in [her] brain somewhere.”

LINK TO VIDEO

8. Fifty-two-year-old accountant (and mother) in Edmonton in Canada, Lisa Stonehouse, dies of a blood clot after AstraZeneca vaccination.

LINK TO VIDEO

9. Canada’s “first death linked to the AstraZeneca vaccine” according to City News. Fifty-four-year-old Francine Boyer, a grandmother, died after developing a blood clot in her brain.

LINK TO VIDEO

10. Twelve days after receiving the Johnson and Johnson “vaccine” Morgan Wolf says she experienced “excruciating pain.” Doctors identified blood clots as the source of Wolf’s pain. As of the video’s recording Wolf was “definitely not 100 percent.”

LINK TO VIDEO

WHAT IS A D-DIMER TEST?

According to the Cleveland Clinic, A D-dimer test is “a blood test that measures D-dimer, which is a protein fragment that your body makes when a blood clot dissolves in your body.” The Cleveland Clinic goes on to note that “D-dimer is normally undetectable or only detectable at a very low level unless your body is forming and breaking down significant blood clots.”

In the video below Emergency Medicine Specialist and member of the Canadian Covid Care Alliance Dr. Rochagné Kilian describes how the clotting phenomena she has observed in the context of the COVID-19 “vaccines” is related to D-dimer levels. Kilian notes how D-dimer levels don’t directly provide a diagnosis, but do indicate any thrombosis in the body. Kilian notes in the video that people who have been “vaccinated” with the COVID-19 injections are displaying as-yet-unseen D-dimer levels.


IN SUMMARY

The evidence supporting the claim that the COVID-19 “vaccines” cause serious, life-threatening blood clots on an unacceptably frequent basis is simply staggering. Paul Offit, Professor of pediatrics at the Children’s Hospital of Philadelphia, notes that “serious blood clots… seem to occur in roughly one person per 500,000 that get the vaccine. The blood clots are serious because they can involve the spleen, they can involve areas of the intestine, and they can involve the brain.” A study published in the journal Maxillofacial Plastic and Reconstructive Surgery on January 13, 2020 found that one of these clotting events occurs every 290,698 “vaccinations” administered; meaning the serious adverse event is almost twice as common as Offit claimed in July of 2021.

The case studies involving blood clots as a result of the COVID-19 “vaccines” are horrific and often fatal. “Within 10 days after receiving a first immunization with ChAdOx1 nCoV-19 [the AstraZeneca “vaccine”], five health care workers 32 to 54 years of age presented with thrombosis in unusual sites and severe thrombocytopenia. Four of the patients had major cerebral hemorrhage,” authors of a study published in The New England Journal of Medicine on April 9, 2021 wrote. The authors described some of these victims undergoing massive thrombotic events in the hospital before dying.

Along with the literature reviews and case studies, instances of blood clotting in VAERS are overwhelming. Searching the (COVID-19 vaccine-only) database for the term “blood clot,” for example, turns up 13,683 results. Thrombosis: 18,870 results. Thrombocytopenia: 6,850 results.

On top of that, there is also testimony from at least one prominent pathologist (Dr. Ryan Cole) and one prominent embalmer (Richard Hirschman), who both describe “incredibly abnormal” blood clots that are now being found frequently in the dead bodies of those who’d been “vaccinated” with the COVID-19 injections.

Finally, putting the rest of the data into crystal clear focus, are the anecdotal stories of those affected by blood clots arising from the COVID-19 “vaccines.” The stories include nightmare encounters with comas, “excruciating pain,” and permanent disabilities. Those who experienced fatal blood clots due to the COVID-19 “vaccines” only leave behind their relatives to speak of their final, terrible moments on Earth.

Feature image: Yale Rosen


Accessibility Toolbar